Skip to content

Cabaletta Bio and Artisan Bio Announce Gene Editing Research and Collaboration Agreement to Develop Next-Generation CAAR T Cell Therapies

PHILADELPHIA and DENVER, July 7, 2020 — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, and Artisan Bio, Inc., a precision cell therapy engineering company, today announced they have signed a research and collaboration agreement to…

Read More

Artisan Bio Announces Global Research and Discovery Collaboration Agreement with Takeda to Develop Next-Generation Cell Therapy Products

Photo by Drew Hays on Unsplash

Artisan Bio Announces Global Research and Discovery Collaboration Agreement with Takeda to Develop Next-Generation Cell Therapy Products Photo by Drew Hays on Unsplash Denver, Colorado – Jan 15, 2020 – Artisan Bio, Inc., a stealth cell therapy engineering company, today announced it has entered into a global research and collaboration agreement with Takeda Pharmaceutical Company…

Read More